BETHLEHEM, Pa., June 1, 2023 /PRNewswire/ -- Levolta Pharmaceuticals, Inc. has entered into an exclusive licensing and distribution agreement for VOLT01 with Tabuk Pharmaceutical Manufacturing Company of Riyadh, Saudi Arabia, for the commercialization of an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region, excluding South Africa. VOLT01 is a patented novel combination drug that has shown promise in Phase II and Phase IIb/III clinical trials in treating OA, which has no cure.
NASHVILLE, Tenn. and RIYADH, Saudi Arabia, March 31, 2022 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), headquartered in Nashville, and Tabuk Pharmaceutical Manufacturing Company, a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East, headquartered in Riyadh, Saudi Arabia, today announced the launch of Cumberland's Vibativ® (telavancin) injection in the Middle East. The announcement follows an agreement between the companies providing Tabuk the exclusive rights to register and promote the product for patients in Saudi Arabia, Jordan and potentially other countries in the Middle East.
Under the terms of this agreement, Tabuk nPharmaceuticals will hold the marketing authorisation for select nspeciality products of Biocon and be responsible to register, import andnpromote them in Saudi Arabia and other Middle East countries
Biotechnology major BioconnNSE 0.13 % on Tuesday said it has inked a pact with Saudi Arabia-based ndrug firm Tabuk Pharmaceutical Manufacturing Company to commercialise nselect speciality products in the Middle East region. Tabuk nPharmaceutical Manufacturing Company is a fully-owned subsidiary of nAstra Industrial Group, a leading pharmaceutical company in the Middle nEast and North Africa (MENA) region. nnnRead more at:nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-ties-up-with-tabuk-pharmaceuticals-to-commercialise-speciality-medicines-in-middle-east/articleshow/88139304.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Tabuk Pharma to commercialize Moderna’s COVID-19 vaccine in Saudi Arabia
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, today announced an agreement to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in Saudi Arabia.
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, today announced an agreement to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in Saudi Arabia.
“This facility... allows us to develop local manufacturing expertise and capabilities to help meet our shared commitment with the government to provide a continued reliable supply of innovative and essential medicines for patients in Saudi Arabia,” Hussein El Hakim, country manager for Pfizer Saudi Limited, said in a statement.